Scientists are actively exploring the clinical potential of psilocybin, the active component found in psychedelic mushrooms. Research ranges from its use as a possible anti-aging treatment to its implications in therapy for depression and anxiety.
Some even propose that it might serve as a treatment for Alzheimer’s, a serious neurodegenerative disease impacting over seven million people in the U.S.
To illustrate, a recent case study published in Frontiers in Neuroscience Neuropharmacology details a woman in her 80s, who had been battling Alzheimer’s for a decade. She was administered a remarkably high dose of psilocybin.
The woman was given five grams of psilocybin mushrooms, significantly more than the typical recreational dose and far higher than what’s usually prescribed in medical contexts. The researchers reported that the woman seemed to undergo what they described as a reawakening.
In just a few days or weeks—exact timing isn’t clear—the patient’s condition shifted from limited communication to improvements like regained urinary control, better mobility, enhanced emotional responsiveness, and more social engagement. Even her ability to retrieve memories reportedly got better.
However, the journey wasn’t easy; she experienced intense sweating while in a deep, sleep-like state after taking the drug. A month later, due to continued improvements, she received a second dose of three grams. There are questions, though, about her ability to consent given her condition.
To be clear, the whole situation is a bit questionable, especially given the extensive media buzz from outlets like the New York Post and Dallas Express, which dubbed it a breakthrough. Critics point out significant issues like the lack of rigorous scientific methods and consent concerns. Notably, the report does not provide evidence that psilocybin reverses Alzheimer’s disease, as noted by neuroscience PhD candidate Rahul Sidhu.
The study was not a controlled trial; the woman’s diagnosis lacked confirmation via biomarkers, and there was no control group or standardized cognitive assessments before she was treated. Observations were largely anecdotal, coming from family and caregivers.
In essence, this case report might come off as more of an unusual tale about an elderly woman receiving a significant drug dose. The authors described the intervention as “exploratory and observational.”
Marcos Lago, a neuroscientist from the University of Sao Paulo, emphasized the need to frame the case carefully. He noted that while improvements were observed, they were temporary, and the report does not endorse psilocybin as a dementia treatment or suggest unsupervised use.
Lago remarked that the significance of this case lies in its potential to raise a hypothesis worthy of further exploration: could psilocybin, under proper medical and ethical conditions, help modulate certain behaviors in patients with severe neurodegenerative diseases?
Skepticism remains due to the affiliation of the study with the “Associação Cruz de Ankh,” which seems to function more as a religious and philosophical organization than a medical one. Their social media presence has celebrated media attention on the case while previously sharing content about subjective experiences with psilocybin.
Nonetheless, there are intriguing aspects to this case. Previous research indicates that new neural connections can arise from experiences, and psilocybin is shown to alter how brain networks communicate.
Furthermore, although the drug appears to promote nerve cell growth and influence brain activity, whether these benefits extend to individuals with Alzheimer’s is still unproven.
In conclusion, while the case study is both compelling and somewhat strange, it certainly warrants continued investigation.
